Show simple item record

dc.contributor.authorJung, J
dc.contributor.authorEggleton, P
dc.contributor.authorRobinson, A
dc.contributor.authorWang, J
dc.contributor.authorGutowski, N
dc.contributor.authorHolley, J
dc.contributor.authorNewcombe, J
dc.contributor.authorDudek, E
dc.contributor.authorPaul, AM
dc.contributor.authorZochodne, D
dc.contributor.authorKraus, A
dc.contributor.authorPower, C
dc.contributor.authorAgellon, LB
dc.contributor.authorMichalak, M
dc.date.accessioned2018-03-26T15:18:16Z
dc.date.issued2018-03-08
dc.description.abstractIn multiple sclerosis (MS), a demyelinating inflammatory disease of the CNS, and its animal model (experimental autoimmune encephalomyelitis; EAE), circulating immune cells gain access to the CNS across the blood-brain barrier to cause inflammation, myelin destruction, and neuronal damage. Here, we discovered that calnexin, an ER chaperone, is highly abundant in human brain endothelial cells of MS patients. Conversely, mice lacking calnexin exhibited resistance to EAE induction, no evidence of immune cell infiltration into the CNS, and no induction of inflammation markers within the CNS. Furthermore, calnexin deficiency in mice did not alter the development or function of the immune system. Instead, the loss of calnexin led to a defect in brain endothelial cell function that resulted in reduced T cell trafficking across the blood-brain barrier. These findings identify calnexin in brain endothelial cells as a potentially novel target for developing strategies aimed at managing or preventing the pathogenic cascade that drives neuroinflammation and destruction of the myelin sheath in MS.en_GB
dc.description.sponsorshipThis work was supported by the Canadian Institutes of Health Research grants MOP-15291, MOP-15415, and PS-153325 to MM and MOP-15291, MOP-86750, and PS-153325 to LBA; by a generous donation from Kenneth McCourt family; and by the Multiple Sclerosis Society of Canada (EGID2426) to CP. Additional support was provided by research grants from the Royal Devon and Exeter Hospital Foundation Trust and Northcott Devon Medical Foundation to PE, JEH, and NJG and a generous donation from Sheryl Moorey’s family. JJ and AK were supported by the Alberta Innovates-Health Solutions (AI-HS) studentship. AK was also supported by a Multiple Sclerosis Society of Canada studentship. ED was supported by the AI-HS postdoctoral fellowship. JW was supported by the Alberta MS Network summer studentship award.en_GB
dc.identifier.citationVol. 3 (5), article e98410en_GB
dc.identifier.doi10.1172/jci.insight.98410
dc.identifier.urihttp://hdl.handle.net/10871/32244
dc.language.isoenen_GB
dc.publisherAmerican Society for Clinical Investigationen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/29515033en_GB
dc.rightsCopyright © 2018, American Society for Clinical Investigation. JCI Insight is an open access journal. All research content is freely available immediately upon publication. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles under the "fair use" limitations of US copyright law.en_GB
dc.subjectCell Biologyen_GB
dc.subjectChaperonesen_GB
dc.subjectMultiple sclerosisen_GB
dc.subjectNeurological disordersen_GB
dc.subjectNeuroscienceen_GB
dc.titleCalnexin is necessary for T cell transmigration into the central nervous systemen_GB
dc.typeArticleen_GB
dc.date.available2018-03-26T15:18:16Z
exeter.place-of-publicationUnited Statesen_GB
dc.descriptionThis is the final version of the article. Available from American Society for Clinical Investigation via the DOI in this recorden_GB
dc.identifier.journalJCI Insighten_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record